Product logins

Find logins to all Clarivate products below.


Parkinson’s Disease – Emerging Therapies – Special Topics: Novel Entrants in the Parkinson’s Disease Market (US)

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g., dopamine agonists, MAO-B inhibitors) to address breakthrough motor symptoms. Pipeline therapies seek to improve therapeutic experience and motor symptom benefit through novel mechanisms, delivery routes, and simplified dosing regimens. The use of newer brands (e.g., Rytary [Amneal], Gocovri [Supernus], Inbrija [Acorda]) has steadily grown, but these agents will face competition from emerging reformulations (e.g., ABBV-951 [AbbVie]) and new molecular entities (NMEs) (IPX-203 [Amneal], dipraglurant [Addex], tavapadon [Cerevel]) in established classes; these reformulations and NMEs have the potential to radically change the clinical management and commercial outlooks in PD. Understanding physicians’ receptivity and anticipated use for new entrants is crucial for developers advancing new drugs in the increasingly crowded, largely generic, and clinically complex market.

Questions answered:

  • How have recently launched brands impacted the market? What are the reasons for prescribing or not prescribing key therapies?
  • How do neurologists rate the performance of key branded therapies?
  • How do neurologists view the clinical profiles of novel therapies for primary motor symptoms, motor fluctuations, and levodopa-induced dyskinesia (LID)? Which will they prefer, and how do they plan to incorporate these agents in treatment?
  • Why will physicians refrain from prescribing emerging brands?

Product description:

Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers gauge the competitiveness and sales potential of late-phase assets in the PD market.

Related Market Assessment Reports

Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…